Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001914245 | SCV002195226 | likely benign | Noonan syndrome 9 | 2024-01-19 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004044057 | SCV004957698 | uncertain significance | Cardiovascular phenotype | 2024-02-05 | criteria provided, single submitter | clinical testing | The c.1714G>A (p.V572I) alteration is located in exon 10 (coding exon 10) of the SOS2 gene. This alteration results from a G to A substitution at nucleotide position 1714, causing the valine (V) at amino acid position 572 to be replaced by an isoleucine (I). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Prevention |
RCV004746510 | SCV005347239 | uncertain significance | SOS2-related disorder | 2024-04-04 | no assertion criteria provided | clinical testing | The SOS2 c.1714G>A variant is predicted to result in the amino acid substitution p.Val572Ile. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.012% of alleles in individuals of Latino descent in gnomAD. Although we suspect that this variant may be benign, at this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |